Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anti-EGF receptor therapy.

G Blackledge1, S Averbuch, A Kay

  • 1AstraZeneca, Alderley Park, Macclesfield, Cheshire, UK.

Prostate Cancer and Prostatic Diseases
|December 24, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Managing the waiting time: Treatment burden and patient complexity among lung transplant candidates - A mixed methods investigation.

Social science & medicine (1982)·2026
Same author

Evidence-based multidisciplinary model of care for newborn screening in spinal muscular atrophy.

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

Clinical standards for antimicrobial stewardship in TB care.

IJTLD open·2025
Same author

An assessment of video-observed treatment as an adherence support tool for patients with drug-resistant TB.

IJTLD open·2025
Same author

Drug susceptibility testing for TB using the Xpert MTB/XDR assay on stool specimens.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2025
Same author

Thoracic and abdominal diagnostic imaging findings in dogs diagnosed with immune-mediated polyarthritis: 71 cases (2011-2023).

The Journal of small animal practice·2024
Same journal

Focal therapy for localized prostate cancer: not all that glitters is gold.

Prostate cancer and prostatic diseases·2026
Same journal

A nationwide histopathology study reflecting the impact of the introduction of MRI in the diagnostic trajectory of prostate cancer in routine clinical care.

Prostate cancer and prostatic diseases·2026
Same journal

En-bloc vs lobe-by-lobe laser prostatectomy: where do we stand?

Prostate cancer and prostatic diseases·2026
Same journal

Response to de Riese et al. regarding "methodological and clinical considerations of MRI-based prostate cancer risk calculators".

Prostate cancer and prostatic diseases·2026
Same journal

Methodological and clinical considerations of MRI-based prostate cancer risk calculators.

Prostate cancer and prostatic diseases·2026
Same journal

Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial.

Prostate cancer and prostatic diseases·2026
See all related articles

Epidermal growth factor receptor (EGFR) inhibitors like ZD1839 show promise for treating hormone-resistant prostate cancer. Early trials indicate this EGFR-tyrosine kinase inhibitor is well-tolerated and effective against various advanced cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The epidermal growth factor receptor (EGFR) pathway is crucial for tumor progression, including cell proliferation, apoptosis, angiogenesis, and metastasis.
  • EGFR signaling plays a key role in the survival mechanisms of hormone-resistant prostate cancer.
  • Novel therapeutic strategies are urgently needed for advanced prostate cancer.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of ZD1839 (Iressa), a selective EGFR-tyrosine kinase inhibitor, in preclinical models and early-phase clinical trials.
  • To investigate the potential of ZD1839 as a treatment for hormone-resistant prostate cancer.

Main Methods:

  • Preclinical studies involving ZD1839 alone and in combination with cytotoxic agents in various tumor cell lines and human tumor xenografts.

Related Experiment Videos

  • Phase I clinical trials in patients with advanced cancers to assess safety, tolerability, and preliminary efficacy.

    • Main Results:

    • ZD1839 demonstrated reversible tumor growth inhibition and delay in preclinical models.
    • Preliminary Phase I data suggest ZD1839 has an acceptable safety profile.
    • Promising clinical efficacy was observed in patients with various advanced tumor types, including hormone-resistant prostate cancer.

    Conclusions:

    • ZD1839 is an orally active, selective EGFR-tyrosine kinase inhibitor with demonstrated preclinical anti-tumor activity.
    • Early clinical data indicate ZD1839 is a potentially valuable therapeutic option for hormone-resistant prostate cancer and other advanced malignancies.
    • Further investigation of ZD1839 in larger clinical trials is warranted.